Anixa Biosciences Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share -0.00
Dividend & YieldN/A$ (N/A)
Beta 1.14
Market capitalization 147.48M
Operating cash flow -5.94M
ESG Scores unknown

Company description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-10-31 2019-10-31 2020-10-31 2021-10-31
Change To Liabilities 101.69k 3.81k -353.45k -96.17k
Total Cashflows From Investing Activities 1.46M -525.46k -305.79k -3.92M
Net Borrowings
Total Cash From Financing Activities 2.53M 5.7M 9.41M 31.57M
Change To Operating Activities 225k 202.92k -169.86k 174.72k
Issuance Of Stock 2.53M 5.69M 9.41M 31.57M
Net Income -14M -11.65M -10.02M -12.95M
Change In Cash -283.48k 435.74k 2.93M 22.71M
Effect Of Exchange Rate
Total Cash From Operating Activities -4.27M -4.74M -6.18M -4.94M
Depreciation 343.73k 466.31k 90.16k 59.86k
Change To Account Receivables -258.99k 271.7k 64.3k
Other Cashflows From Financing Activities 14.03k 14.03k
Change To Netincome 9.31M 5.96M 4.21M 7.88M
Capital Expenditures -38.4k -175.46k -15.79k

Income Statement 2018-10-31 2019-10-31 2020-10-31 2021-10-31
Research Development 6.81M 5.47M 4.38M 6.19M
Income Before Tax -14.24M -11.82M -10.09M -13.13M
Net Income -14M -11.65M -10.02M -12.95M
Selling General Administrative 6.91M 5.66M 5.93M 7.07M
Gross Profit 344.09k 83.75k 127.5k
Ebit -13.71M -11.47M -10.32M -13.14M
Operating Income -13.71M -11.47M -10.32M -13.14M
Interest Expense
Income Tax Expense
Total Revenue 1.11M 250k 512.5k
Cost Of Revenue 768.41k 166.25k 385k
Total Other Income ExpenseNet -537k -347.4k 222.84k 7.77k
Net Income From Continuing Ops -14.24M -11.82M -10.09M -13.13M
Net Income Applicable To Common Shares -14M -11.65M -10.02M -12.95M

Balance Sheet Statement 2018-10-31 2019-10-31 2020-10-31 2021-10-31
Total Liabilities 1.27M 1.48M 1.19M 1.49M
Total Stockholder Equity 5.43M 5.24M 8.76M 35.44M
Other Current Liabilities
Total Assets 6.45M 6.29M 9.45M 36.26M
Common Stock 189.09k 203.32k 242.49k 300.51k
Other Current Assets
Retained Earnings -170.17M -181.82M -191.84M -204.79M
Treasury Stock
Cash 3.06M 3.49M 6.42M 29.13M
Total Current Liabilities 1.27M 1.48M 1.19M 1.27M
Other Stockholder Equity
Property, Plant, and Equipment 72.67k 200.57k 54.34k 253.96k
Total Current Assets 5.54M 6.09M 9.37M 36M
Net Tangible Assets 4.6M 5.24M 8.76M 35.44M
Net Receivables 306.99k 66.53k
Accounts Payable 582.01k 585.82k 232.37k 136.2k


Insider Transactions

Here are the insider transactions of stock shares related to Anixa Biosciences Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
TITTERTON LEWIS H JRConversion of Exercise of derivative security at price 2.58 per share.D2022-09-29Director40k
KUMAR AMITConversion of Exercise of derivative security at price 2.58 per share.D2022-09-15Chief Executive Officer640k
TITTERTON LEWIS H JRStock Gift at price 0.00 per share.D2022-09-14Director300k
TITTERTON LEWIS H JRConversion of Exercise of derivative security at price 2.58 per share.D2022-06-24Director46k
TITTERTON LEWIS H JRPurchase at price 2.79 per share.D2022-04-26Director10k
CATELANI MICHAEL JPurchase at price 2.66 per share.D2022-04-21President5.5k
CATELANI MICHAEL JPurchase at price 2.53 per share.D2022-04-20President2.51k
TITTERTON LEWIS H JRPurchase at price 3.28 per share.D2022-01-12Director5k
TITTERTON LEWIS H JRPurchase at price 3.20 per share.D2022-01-11Director2k
TITTERTON LEWIS H JRPurchase at price 3.08 per share.D2022-01-10Director6k
TITTERTON LEWIS H JRPurchase at price 3.08 per share.D2022-01-07Director11k
KUMAR AMITPurchase at price 3.00 per share.D2022-01-07Chief Executive Officer20k
TITTERTON LEWIS H JRPurchase at price 4.76 per share.D2021-10-29Director18.24k
KUMAR AMITPurchase at price 4.77 per share.D2021-10-29Chief Executive Officer2k
TITTERTON LEWIS H JRPurchase at price 4.21 per share.D2021-07-26Director30k
KUMAR AMITPurchase at price 4.28 per share.D2021-07-23Chief Executive Officer5k
BASKIES ARNOLD MPurchase at price 4.33 per share.D2021-07-23Director19k
TITTERTON LEWIS H JRPurchase at price 3.65 - 4.07 per share.D2021-07-16Director12.2k
KUMAR AMITPurchase at price 3.94 per share.D2021-07-16Chief Executive Officer10k
BASKIES ARNOLD MPurchase at price 3.90 per share.D2021-07-15Director20k
GOTTSCHALK EMILYPurchase at price 3.96 per share.D2021-07-15Director20.07k
TITTERTON LEWIS H JRPurchase at price 3.72 per share.D2021-07-14Director23.3k
GOTTSCHALK EMILYPurchase at price 4.49 per share.D2021-04-23Director10k
BASKIES ARNOLD MPurchase at price 3.91 per share.D2021-04-20Director10k
TITTERTON LEWIS H JRPurchase at price 3.99 per share.D2021-04-19Director5k
TITTERTON LEWIS H JRPurchase at price 4.84 per share.D2021-03-25Director45k
KUMAR AMITPurchase at price 4.86 per share.D2021-03-25Chief Executive Officer5k
BASKIES ARNOLD MPurchase at price 4.80 per share.D2021-03-25Director10k
GOTTSCHALK EMILYPurchase at price 4.88 per share.D2021-03-25Director15.6k
TITTERTON LEWIS H JRStock Gift at price 0.00 per share.D2021-02-03Director200k
KUMAR AMITPurchase at price 3.73 per share.D2021-01-29Chief Executive Officer10k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Anixa Biosciences Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Anixa Biosciences Inc

Here is the result of two systematic investment strategies applied to Anixa Biosciences Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Anixa Biosciences Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Anixa Biosciences Inc:

Anixa Biosciences Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 44.5% on the backtest period.

Performance at glance

Performance

44.5 %

Latent gain

779.1 $

Invested capital

1750.74 $

Annualized return

10.85 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Anixa Biosciences Inc

This is the result of two momentum investment strategies applied to Anixa Biosciences Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Anixa Biosciences Inc

The following chart shows all the entries opened by the momentum investment system on Anixa Biosciences Inc:

Anixa Biosciences Inc momentum entries
  • The first momentum investment strategy would give 60.56% of return on Anixa Biosciences Inc. That represents 2875.65$ of latent gain with 4748.73$ of employed capital.
  • The second momentum investment strategy would give 56.74% of return on Anixa Biosciences Inc. That represents 2128.99$ of latent gain with 3752.39$ of employed capital.
Performance at glance (1Q Momentum)

Performance

60.56 %

Latent gain

2875.65 $

Invested capital

4748.73 $

Annualized return

57.31 %
Performance at glance (2Q Momentum)

Performance

56.74 %

Latent gain

2128.99 $

Invested capital

3752.39 $

Annualized return

15.67 %

Momentum equity curve on Anixa Biosciences Inc

The following chart shows the equity curve of the two momentum strategies applied to Anixa Biosciences Inc:

Anixa Biosciences Inc momentum equity

Note: the dividends potentially given by Anixa Biosciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anixa Biosciences Inc

The following chart shows the employed capital evolution of the two momentum strategies on Anixa Biosciences Inc since the beginning:

Anixa Biosciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Anixa Biosciences Inc

Buy the dip entry openings on Anixa Biosciences Inc

Anixa Biosciences Inc

The performance achieved by the robo-advisor on Anixa Biosciences Inc is 120.35%. That represents 301.92$ of latent gain with 250.86$ of employed capital. The following chart shows Anixa Biosciences Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Anixa Biosciences Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

120.35 %

Latent gain

301.92 $

Invested capital

250.86 $

Annualized return

57.31 %

Equity curve of the strategy applied to Anixa Biosciences Inc

The following chart shows the result of the investment strategy applied to Anixa Biosciences Inc:

Anixa Biosciences Inc

Note: the dividends potentially given by Anixa Biosciences Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Anixa Biosciences Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Anixa Biosciences Inc:

Anixa Biosciences Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Anixa Biosciences Inc

In this section, I will compare the three previous investment strategies applied to Anixa Biosciences Inc.

Equity curve comparison on Anixa Biosciences Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Anixa Biosciences Inc investment strategy comparison

Employed capital comparison on Anixa Biosciences Inc

Anixa Biosciences Inc investment comparison

Performance comparison on Anixa Biosciences Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 44.5% 779.1$ 1750.74$ 10.85%
Momentum 1 quarter 60.56% 2875.65$ 4748.73$ 15.69%
Momentum 2 quarters 56.74% 2128.99$ 3752.39$ 15.67%
Non-directional 120.35% 301.92$ 250.86$ 57.31%
Annualized return comparison

Automatic investment

10.85 %

Momentum 1Q

15.67 %

Momentum 2Q

15.67 %

Non-directional

57.31 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Anixa Biosciences Inc:

Positive correlations

Most correlated stocks this year

  • Anixa Biosciences Inc

  • Most correlated stocks last 3 months

  • AUO Corp
  • ARGONAUT GOLD INC.
  • KLA Corp
  • Anixa Biosciences Inc
  • Descartes Systems Group Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Anixa Biosciences Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Anixa Biosciences Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Anixa Biosciences Inc
    Country United States
    City San Jose
    Address 3150 Almaden Expressway
    Phone 408 708 9808
    Website www.anixa.com
    FullTime employees 4
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ANIX
    Market www.nasdaq.com

    Anixa Biosciences Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown